Alliance Global Partners Initiates Coverage On AcelRx Pharmaceuticals with Buy Rating, Announces Price Target of $4.25
Portfolio Pulse from Benzinga Newsdesk
Alliance Global Partners analyst James Molloy has initiated coverage on AcelRx Pharmaceuticals with a Buy rating and a price target of $4.25.
October 02, 2023 | 12:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AcelRx Pharmaceuticals has been given a Buy rating by Alliance Global Partners with a price target of $4.25.
The initiation of coverage by Alliance Global Partners with a Buy rating and a price target of $4.25 indicates a positive outlook for AcelRx Pharmaceuticals. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100